• TARAKA SUNIL KUMAR K Department of Pharmaceutics, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad-500072, Telangana, India.
  • MOHAN VARMA M Department of Pharmaceutics, Sri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India.
  • RAVI PRAKASH P Department of Pharmaceutics, Creative Educational Society’s College of Pharmacy, Kurnool, Andhra Pradesh, India.



Enzalutamide,, Nil, Prostate cancer,, Solid lipid nanoparticle,, Trimyristin,, Zero-order kinetics


Objective: The primary motive behind this investigation is to develop and optimize the solid lipid nanoparticles formulation of enzalutamide for the effective drug delivery.

Materials and Methods: The formulation variables were optimized using design of experiments. Box–Behnken design was used for the study and the results were analyzed using response surface methodology. The prepared nanoformulation was characterized for particle size, zeta potential, surface morphology, X-ray diffractometry (XRD), in vitro drug release kinetics, and stability study.

Results: The influence of formulation variables, drug-to-lipid ratio, concentration of phosphatidylcholine, and concentration of poloxamer 188 were evaluated by regression analysis. The optimized formulation (F3) was found to have the minimum particle size (253 nm) with maximum entrapment efficiency (89.72%) and drug loading (23.84%). From SEM studies, the data showed a spherical shape for enzalutamide nanoparticles with uniform and relatively narrow particle distribution. From XRD examines, it is demonstrative that the drug was not in crystalline form in nanoformulation when compared with pure drug. In vitro release studies disclosed that maximum cumulative drug release was attained by F3 (99.72%) in controlled manner. The optimized formulation of enzalutamide followed zero-order release kinetics with a strong correlation coefficient (R2 = 0.9994).

Conclusion: The nanoformulation prepared under optimized conditions is in concurrence with the expected results. The SLN formulation can be used as a potential carrier for the effective delivery of enzalutamide.


Begum MY, Reddy GP. Formulation and evaluation of dasatinib loaded solid lipid nanoparticles. Int J Pharm Pharm Sci 2018;10:14-20.

Priyanka K, Sathali AA. Preparation and evaluation of montelukast sodium loaded solid lipid nanoparticles. J Young Pharm 2012;4:129-37.

Ekambaram P, Abdul HS. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011;3:216-20.

Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001;47:165 96.

Radomska-Soukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:411-8.

Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011;8:1407-24.

Abather AS, Rassol AA. Formulation and evaluation of silibinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract. Int J Pharm Pharm Sci 2014;6:55-67.

Golshayan AR, Antonarakis ES. Enzalutamide: An evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013;8:27-35.

Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharm Res 2008;25:781-91.

Montgomery DC. Design and Analysis of Experiments. New York: John Wiley and Sons Inc.; 2007.

Myers RH, Montgomery DC, Anderson-Cook CM. Response Surface Methodology: Process and Product Optimization Using Designed Experiments. United States: Wiley; 2009.

Piepel GF. Programs for generating extreme vertices and centroids of linearly constrained experimental regions. J Qual Technol 1988;20:125 39.



How to Cite

TARAKA SUNIL KUMAR K, MOHAN VARMA M, and RAVI PRAKASH P. “DEVELOPMENT AND OPTIMIZATION OF ENZALUTAMIDE-LOADED SOLID LIPID NANOPARTICLES USING BOX–BEHNKEN DESIGN”. Asian Journal of Pharmaceutical and Clinical Research, vol. 12, no. 6, June 2019, pp. 67-76, doi:10.22159/ajpcr.2019.v12i6.31617.



Original Article(s)